Clinical trial
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or…
NCT00100854 · Translational Oncology Research International, Other · Completed
Key facts
| NCT number | NCT00100854 |
|---|---|
| Title | Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Randomized, Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva®) and Fulvestrant (Faslodex®) Versus Erlotinib (Tarceva®) Alone in Advanced Non-Small Cell Lung Cancer Patients |
| Lead sponsor | Translational Oncology Research International, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride, fulvestrant |
| Enrollment | 108 |
| Start date | Oct 28, 2004 |
| Primary completion | Sep 5, 2018 |
| Completion | Sep 5, 2018 |
| First posted | Jan 7, 2005 |
| Last update posted | Mar 5, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: